Navidea Biopharmaceuticals, Inc. is a leader in precision medicine with immuno-targeted products.
Location: United States, Ohio, Dublin
Employees: 11-50
Total raised: $60M
Founded date: 1983
Investors 2
| Date | Name | Website |
| - | Hercules C... | htgc.com |
| - | CRG | crglp.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.05.2015 | - | $60M | - |
Mentions in press and media 10
| Date | Title | Description | Source |
| 04.02.2022 | Navidea Biopharmaceuticals : Announces Settlement of Platinu... | Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance No... | marketscre... |
| 17.12.2021 | Navidea Biopharmaceuticals : Terminates Stock Purchase Agree... | Navidea Biopharmaceuticals Terminates Stock Purchase Agreement DUBLIN, Ohio--(BUSINESS WIRE)--Navid... | marketscre... |
| 10.12.2021 | Navidea Biopharmaceuticals : Announces Business Update Call ... | Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composit... | marketscre... |
| 27.10.2021 | Navidea Biopharmaceuticals Announces Resignation of Jed A. L... | Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin DUBLIN, Ohio-(BUSINESS WIRE)-Octo... | marketscre... |
| 20.09.2021 | Navidea Biopharmaceuticals : Announces Changes to Board of D... | DUBLIN, Ohio - Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ('Navidea' or the 'Company'), ... | marketscre... |
| 17.09.2021 | Navidea Biopharmaceuticals : Announces Changes to Board of D... | Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition DUBLIN, Ohio--(BUSIN... | marketscre... |
| 14.05.2015 | Navidea lands $60m for Lymphoseek | Navidea (NYSE:NAVB) is getting a loan of up to $60 million it plans to use to retire debt and spur w... | massdevice... |
| 22.08.2013 | Navidea’s Alzheimer’s imaging agent moves into Phase 3 with ... | The presence of amyloid plaques in the brain has been considered a hallmark of neurodegenerative dis... | medcitynew... |
| 13.03.2013 | Cancer: FDA approves Navidea’s Lymphoseek imaging agent | The FDA approved Navidea Biopharmaceuticals’ Lymphoseek radioactive imaging agent, an injectable dru... | massdevice... |
| - | Navidea’s Alzheimer’s imaging agent moves into Phase 3 with ... | Navidea Biopharmaceuticals (NYSE:NAVB) is getting some financial support from the NIH for its Alzhei... | medcitynew... |